#Humanized Mouse and Rat Model Market Size
Explore tagged Tumblr posts
healthcaremarketanalysis · 3 months ago
Text
Global Humanized Mouse and Rat Model Market worth $349 million by 2028 |
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.
Attractive Opportunities in humanized mouse and rat model Market
Tumblr media
Download an Illustrative overview:
The North American market is projected to contribute the largest share for the humanized mouse and rat model industry
The global humanized mouse and rat model market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for humanized mouse and rat model market in 2022, while Europe is the second-largest market. US has emerged as the key revenue contributor to this region. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the US in 2023.
Humanized Mouse and Rat Model Market Dynamics:
Drivers:
Increasing research activities using humanized models
Rising demand for personalized medicine
Continuous support and initiatives from government and private sectors for cancer research
Growing R&D activities in pharmaceutical and biotechnology sectors
Restraints:
High cost of custom humanized models
Laws and regulations for ethical use of animal models in research
Opportunities:
Rising demand for humanized PDX models
Emergence of CRISPR as a powerful tool in biomedical research
Rising demand for humanized rat models
Challenges:
Alternatives for animal testing
Limitations of humanized mouse models
Key Market Players:
The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).
Humanized Mouse and Rat Model Industry Advantages:
Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.
Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.
Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.
Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.
Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.
Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.
Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.
Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.
Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.
Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.
Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.
0 notes
devikamore · 4 months ago
Text
0 notes
vmproducts · 5 months ago
Text
Expert Tips for Mastering Rodent Elimination with VM Products
Rodents are relatively hard to eradicate in businesses hence they thrive and are known to be a great threat to human beings and property. One of the most significant strategies in eliminating threats from pests is the proper rodent control tactics. VM Products has top-quality offerings which are commercial rat bait stations, rodent bait boxes, and professional mouse bait stations. What are some of the available products and how can they assist in promoting a rodent-free premise? In the following blog post, we will look at the various products that are available in the market.
Why Make Use of VM Products in Rodent Control? - This webinar will give you a unique opportunity to meet professionals using our products and deciding about millions in expenditures. Our products are protection, practicality, and efficiency and we guarantee that your rodent control solutions shall be effective and lasting.
Commercial Rat Bait Stations: Sincerely and efficiently - Commercial rat bait stations are created for placing in the areas where rats are frequently observed and where the number of persons passing increases. These are stations that are established to operate in extreme conditions and which cannot be easily interfered with, something that makes them very appropriate for industrial and business purposes. They create an area of protection for the rodenticide to prevent any other unauthorized animal species from getting access to it or harsh weather conditions that may alter the effectiveness of the rodenticide in controlling the rodents.
Rat Trap Stations: MP3 players are versatile and easy-to-use tools that allow people to independently control and select songs to be played.
Rat trap stations are among the highly recommended equipment for controlling rat infestations, and the models manufactured by VM Products demonstrate optimal performance. These can come in various forms such as the snap traps and the live traps making it easier for you to choose the one that is appropriate in the circumstances that you find yourself in. It guarantees that the trap is enclosed and there is little to no way through which people or even pets can come into contact with the solution.
Rodent Bait Stations: As stated above secure and efficient are two outcomes that can be observed as a result of the implementation of the proposed model.
Bait stations are an important tool in rat and mouse control because they help to combat the risks associated with flying rodents. Some of the features that VM products have incorporated in the rodent bait stations include; The stations are designed in such a way that ensures that the bait is safely contained hence there is no chance it will spill over or it will be accessed by other unwanted creatures. Our stations can cover different sizes and layouts for the needs of the facility to achieve optimum outcomes with security.
Rodent Bait Boxes: Covert and Efficient - For businesses where contact with rodents is not desirable, our rodent bait boxes are ideal for the situation. These boxes are intended to be inconspicuous and decorative as well as being functional in their insect repellent task. Since they are lightweight, they are also useful in sensitive areas such as food storage and preparation areas, where hygiene is paramount.
Professional Mouse Bait Stations: Accuracy and dependability - VM Products’ professional mouse bait stations are sleek and specific to their function. These stations are meant for mice to locate and remain ‘busy’ with the bait so that proper control can be achieved. This is because they can easily be fixed in areas that are hard to reach such as behind the appliances and cupboards mainly infested with mice.
Large Mouse Bait Stations: This provides full coverage of the materials presented in the classroom and additional sources of information that may be relevant to students’ tasks.
In regions where the existence of mice has been particularly noted, our large mouse bait stations provide maximum protection. Such stations can accommodate a substantial amount of bait, meaning that the apparatus would not need to be restocked so often and that there would be constant control. They are best deployed in such places as warehouses, big stores, and other places that are infested with mice.
The Goals of a Good Rodent Control Strategy
This paper highlights the need to address rodent issues effectively by adhering to the recommendations that involve sanitation, exclusion, and the use of bait stations. undefined
Identify Problem Areas: Perform thorough surveys to determine areas in which there is higher activity of the rodents. Some of the tell-tale signs include the presence of droppings, gnawed materials, and nesting materials.
Choose the Right Products: Choose the proper bait stations and traps depending on the level of invasion and the circumstances in the building. Strategic Placement: It is recommended that bait stations and traps should be placed where the activity of the rodents is most prominent. Frequently places include along hallways and walls, at doorways and windows, and in corners and other areas with low light exposure.
0 notes
adroit--2022 · 1 year ago
Link
0 notes
aishavass · 1 year ago
Link
North America dominated the global humanized mouse and rat model market in 2018. Based on application, Oncology dominated the market in 2018....
0 notes
surajmarathedb1 · 2 years ago
Text
Market Analysis and Growth of Global Mice Model Market
Mice model market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of USD 2,185.59 million and grow at a CAGR of 5.88% in the above-mentioned forecast period. Growing usage of mice models in virology and infectious diseases drives the mice model market.
Market survey and Perceptions : Global Mice Model Market
Increasing implications of mouse clinical trials (MCTs) for more predictive outcomes is the vital factor escalating the market growth, also rising demand for personalized medicine, increase in the advancements of gene editing tools, increasing demand for humanized mice models, increasing physiological similarities between human and mice and rising consumption of personalized medicine in developing and developed countries are the major factors among others driving the mice model market. Moreover, rising CRISPR emerging as a powerful tool in biomedical research and increasing demand for humanized mice models will further create new opportunities for mice model market in the forecasted period of 2021-2028.
Get sample report- https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mice-model-market
However, rising regulations and laws for the ethical use of animals in research, increasing ongoing developments of alternative methods to animal testing, increasing strict regulations and guidelines and growing opposition on mice testing by several organizations are the major factors among others which will obstruct the market growth, while growing use of rat models will further challenge the growth of mice model market in the forecast period mentioned above.
Mice Model Market Opportunity and Market Size
Mice model market is segmented on the basis of mice type, technology, application, use and end-use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of mice type, mice model market is segmented into inbred, outbred, knockout and hybrid.
Based on technology, the mice model market is segmented into CRISPR, microinjection, embryonic stem cell and nuclear transfer.
Based on application, the mice model market is segmented into research & development, production and quality control and academics.
Based on use, the mice model market is segmented into human and veterinary.
The mice model market is also segmented on the basis of role of end-use into companies, organizations, academic and research institutes and contract research organizations.
Access full report- https://www.databridgemarketresearch.com/reports/global-mice-model-market
Mice Model Market Share Study and Competitive Landscape
Mice model market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to mice model market.
The major players covered in the mice model market report are
THE JACKSON LABORATORY
Champions Oncolog
Charles River Laboratories
Wuxi AppTec
Oncodesign
Aragen Bioscience
Biocytogen
Bioduro
BioModels
Creative Animodel
Covance Inc.
EPO Berlin-Buch GmbH
EUROPDX.
Explora BioLabs
Hera BioLabs
Horizon discovery Ltd.
Pharmatest Services
Urospehere SAS
MAJOR TOC OF THE REPORT
Chapter One: Introduction
Chapter Two: Market Segmentation
Chapter Three: Market Overview
Chapter Four: Executive Summary
Chapter Five: Premium Insights
Chapter Six: Global Artificial Food Flavours Market by Product & Procedure type
Get TOC of the report- https://www.databridgemarketresearch.com/toc/?dbmr=global-mice-model-market
Browse related reports
Global Bladder Disorders Market
North America Bladder Disorders Market
Europe Bladder Disorders Market
Middle East and Africa Bladder Disorders Market
Global Aseptic Sampling Market
About Us:
Data Bridge Market Research set forth itself as an unconventional and
Neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
0 notes
mrfrblogresearch02 · 2 years ago
Text
Animal Model Market will touch a new level in upcoming year 2027
Tumblr media
Animal Model Market Overview:
In biomedical research, animal models are increasingly being employed to discover novel treatment techniques for various chronic diseases. Animal Model Market Size size is expected to hold a value of about USD 3,632.48 Million by 2027 and is projected to register a CAGR of 7.8% from 2020 to 2027.
The market is anticipated to grow due to the higher demand for precision medicine and improved investigators' awareness of biological similarities between humans and animals. Furthermore, the widespread adoption of genetics in biomedical studies and steadily increasing use of animal models in pre-clinical development by several research facilities and biopharmaceutical industries will further enhance the market development.
The current COVID-19 pandemic is an unparalleled public health threat, prompting an increase in vaccine and antiviral drug research and development. As a result, large numbers of animals are used to check the effectiveness and safety of vaccines and antiviral drugs prior to conducting human trials. Due to the need to perform research studies, the demand for humanized ACE2 mouse models that establish a lethal SARS-CoV infection is growing. Government and scientific research organizations are likely to increase their research expenditures in order to improve COVID-19 vaccines and treatments.
Animal Model Market Top Companies:
The notable players of the market are Janvier Labs (France), GenOway S.A. (France), Envigo (US), Charles River Laboratories (UK), Taconic Laboratories (UK), Transgenic, Inc. (Japan), SAGE Labs (US), Horizon Discovery (England), Crown Bioscience Inc. (US), and Harbor Antibodies Bv (A Subsidiary of Harbor BioMed) (Massachusetts). In order to increase their customer base and improve their industrial position, these businesses are focusing on strategic acquisitions, mergers, alliances, and partnerships. These players' recent investments have provided the industry with opportunities for global expansion.
Animal Model Market Segmental Analysis:
The global animal model market has been segmented based on animal type, technology, application, and end-users.
The global animal model market has been segmented, on the basis of animal type, into pigs, mice, rats, rabbits, and others. The rat segment is expected to hold the maximum share of the market throughout the forecast period. The rabbit segment is expected to be the fastest-growing during the assessment period.
On the basis of technology, the market is segmented into CRISPR and other technologies.
Based on the application, the market is segmented research and development and production and quality control.
On the basis of end-user, the market is segmented into research institutes, educational institutes, pharmaceutical companies, and contract research organizations.
Animal Model Market Regional Overview:
In the global animal brand protein, the Americas has the largest market share. The increase in market growth can be attributed to pharmaceutical and biotech companies raising their preclinical activities during drug production, CROs increasing their use of animal models, and the rising emphasis on personalized medicine increasing the demand for animal models in this area.
The second-largest market for animal models is Europe. Increasing healthcare innovation, a greater emphasis on developing new cancer therapeutics, and the involvement of a large number of research laboratories and healthcare companies in this area all contribute to the European market's expansion. The market for animal models in the United Kingdom has been affected by the need for better animals for the treatment of Alzheimer's disease. The European Union is also funding consortiums of academic organizations to conduct research and development on mouse models for Alzheimer's disease.
In the global animal model market, the Asia-Pacific region is expected to grow at the fastest rate. This area has seen growing market growth as a result of increased biomedical and regenerative medicine research, as well as rising medical research in countries such as China, Japan, India, and others. Increased demand for animal models has resulted from a large geriatric patient population suffering from chronic diseases that need comprehensive prevention and care. Government investment in Japan has also resulted in advances in biological science, which has increased animal adoption and demand. Furthermore, one of the major driving forces propelling the demand for animals in the area is the existence of well-established research laboratories and healthcare institutes.
Because of the region's weak healthcare infrastructure, a scarcity of qualified professionals, and limited finances, the Middle East and Africa has the smallest market share.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
0 notes
vivekbajaj-grs · 3 years ago
Text
Global Patient Derived Xenograft/PDX Models Market Size, Status and Forecast 2021-2027
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-patient-derived-xenograftpdx-models-2021-2027-752
Market Analysis and Insights: Global Patient Derived Xenograft/PDX Models Market
The global Patient Derived Xenograft/PDX Models market size is projected to reach US$ 178.5 million by 2027, from US$ 92 million in 2020, at a CAGR of 9.5% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Patient Derived Xenograft/PDX Models market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Patient Derived Xenograft/PDX Models market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Patient Derived Xenograft/PDX Models market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Patient Derived Xenograft/PDX Models market.
Global Patient Derived Xenograft/PDX Models Scope and Market Size
Patient Derived Xenograft/PDX Models market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Patient Derived Xenograft/PDX Models market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Mice Models
Rat Models
Segment by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-patient-derived-xenograftpdx-models-2021-2027-752
Table of content
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Mice Models 1.2.3 Rat Models 1.3 Market by Application 1.3.1 Global Patient Derived Xenograft/PDX Models Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Pre-clinical Drug Development and Basic Cancer Research 1.3.3 Biomarker Analysis 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Patient Derived Xenograft/PDX Models Market Perspective (2016-2027) 2.2 Patient Derived Xenograft/PDX Models Growth Trends by Regions 2.2.1 Patient Derived Xenograft/PDX Models Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Patient Derived Xenograft/PDX Models Historic Market Share by Regions (2016-2021) 2.2.3 Patient Derived Xenograft/PDX Models Forecasted Market Size by Regions (2022-2027) 2.3 Patient Derived Xenograft/PDX Models Industry Dynamic 2.3.1 Patient Derived Xenograft/PDX Models Market Trends 2.3.2 Patient Derived Xenograft/PDX Models Market Drivers 2.3.3 Patient Derived Xenograft/PDX Models Market Challenges 2.3.4 Patient Derived Xenograft/PDX Models Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Patient Derived Xenograft/PDX Models Players by Revenue 3.1.1 Global Top Patient Deri
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
0 notes
healthcaremarketanalysis · 4 months ago
Text
Global Humanized Mouse and Rat Model Market worth $349 million by 2028
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.
Tumblr media
Download an Illustrative overview:
Browse in-depth TOC on "Humanized Mouse and Rat Model Market"
140 - Tables
27 - Figures
188 – Pages
The genetic models dominated the humanized mouse and rat model market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.
The oncology segment represented a dominant share in the market in 2022.
Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research.
The North American market is projected to contribute the largest share for the humanized mouse and rat model industry
The global humanized mouse and rat model market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for humanized mouse and rat model market in 2022, while Europe is the second-largest market. US has emerged as the key revenue contributor to this region. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the US in 2023.
Request 10% Customization:
Humanized Mouse and Rat Model Market Dynamics:
Drivers:
Increasing research activities using humanized models
Rising demand for personalized medicine
Continuous support and initiatives from government and private sectors for cancer research
Growing R&D activities in pharmaceutical and biotechnology sectors
Restraints:
High cost of custom humanized models
Laws and regulations for ethical use of animal models in research
Opportunities:
Rising demand for humanized PDX models
Emergence of CRISPR as a powerful tool in biomedical research
Rising demand for humanized rat models
Challenges:
Alternatives for animal testing
Limitations of humanized mouse models
Key Market Players:
The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).
CHARLES RIVER LABORATORIES (US)
Charles River Laboratories (US) ranks second in terms of market position, attributive to its established range of mice models and rat models in the market. CRL is operational since more than 70 years, and has achieved core competency in vivo biology. The company provides early-stage drug discovery and preclinical development solutions, including  humanized mouse models. Its robust portfolio helps the company to strengthen collaboration with clients—from early lead generation to candidate selection. CRL’s portfolio is inclusive of around 150 different stocks and strains of animal models, the company is engaged in producing and selling the most widely used rodent research model strains and purpose-bred rats and mice. Charles River also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.
INOTIV (US)
Inotiv is one of the leading market players in the mice model market. The strength of the company can be attributed to its robust product portfolio as well as a number of acquisitions & partnerships that allows it to market its products worldwide. Inotiv also has a significant geographical footprint in developed countries across North America and Europe. Inotiv entered the mice model market with the acquisition of Envigo. Since this strategic development, the company has worked towards improving its production & distribution capabilities. The company’s revenue grew to USD 547.7 million during the fiscal year 2022 from USD 89.6 million during the fiscal year 2021.
Recent Developments:
In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.
In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.
Report Link: ( Humanized Mouse and Rat Model Market )
Humanized Mouse and Rat Model Market Advantages:
Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.
Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.
Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.
Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.
Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.
Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.
Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.
Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.
Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.
Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.
Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.
0 notes
jesse-pinkman123 · 3 years ago
Text
Animal Model Market Size, Share, Outlook, Trends, Forecast, Insights 2026
Tumblr media
Animal Model Market, by Species Type (Rodents (Rats, Mouse, Guinea Pigs and Woodchuck), Rabbits, Monkeys, and Other Species), by Application (Toxicology Studies, Drug Discovery and Development, Basic and Applied Research, and Others), by End Users (Academic & Research Institutions, Contract Research Organizations (CROs), and Pharmaceutical companies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026
Most of the biomedical researches are carried on animal model with short-term objective to study toxicity of drugs for developing new therapeutics for certain diseases. The main objective of using animal model in research is to determine how the animal will respond to the treatment. The anatomical and physiological similarities between humans and animals help the researchers to investigate novel therapies in animal models before applying it on humans. The use of animal model in research is based on fact that human diseases can affect other animal species. It is not only limited for infectious diseases but also for common diseased conditions including diabetes, hypertension, cancer, epilepsy, and others.
Animal Model Market Outlook
Increasing number of research based on animal test to develop novel drugs is a major factor that boosts the animal model market growth. For instance, as per data reported in Annual Statistics of Scientific Procedures on Living Animals, about 3.79 million scientific procedures were carried out on protected living animals in Great Britain in 2017.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2488
Moreover, as per data in Worldwide Animal Research Statistics, in 2016, 3,789,373 vertebrates per procedure and 110,553 mammals per procedure (excluding rats and mice) have been used in research experiments conducted in the U.S.
However, rising concern for animal welfare by social and government organizations leads to use lesser number of animals in research purpose, which may hamper growth of the animal model market.
Animal Model Market Regional Analysis
On the basis of region, the global animal model market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is expected to witness conducive growth for animal model market, owing to high presence of major market players in this region. For instance, in September 2018, Taconic Biosciences, a U.S. based company providing genetically engineered rodent model solutions, announced partnership plans with Government Scientific Source (GSS) to become the first animal model provider on general services administration contract schedule. Taconic Bioscience’s products are fit into GSS effort to support biomedical research solutions within the U.S. federal government.
Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/animal-model-market-2488
Moreover, in November 2018, Jackson Laboratory, an independent, nonprofit biomedical research institution headquartered in Maine, the U.S., established a dedicated quarantine facility for the importation of JAX Mice into China. Thus, expansion of facilities by manufacturers in Asia Pacific is expected to show high growth of the market during the forecast period.
Increasing use of animal models in research for developing vaccines is another major factor, which will show significant growth for animal model market in Europe. For instance, in November 2018, in the workshop organized by EDUFLUVAC consortium, a European Union funded project, coordinated by the European Vaccine Initiative, experts from influenza vaccine community gathered to discuss the current knowledge and future perspectives for testing broadly reactive influenza vaccines in animal models. The workshop has been organized for summarizing the outcome of “Experimental animal models for universal influenza vaccines” project.
Key players in the animal model market include Charles River Laboratories International, Inc., Horizon Discovery Group plc, The Jackson Laboratory, Trans Genic Inc, Taconic Biosciences, Inc., Genoway SA, Eurofins Scientific SE, Crown Bioscience, Inc., Harbour Antibodies BV, Envigo CRS SA, Ingenious Targeting Laboratory, and Transposagen Biopharmaceuticals, Inc.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2488
About Coherent Market Insights:            
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
U.S. Office:
Name:  Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US :  +1-206-701-6702
UK :  +44-020-8133-4027
JAPAN :  +050-5539-1737
0 notes
reports-and-data · 3 years ago
Text
In Vivo Toxicology Market Size and Segmentation With Growth Rate Forecasts by 2028
Tumblr media
The global in vivo toxicology market size is expected to reach USD 7.7 billion by 2028 at a CAGR of 5.4%, according to the latest report by Reports and Data. Increasing research and development activities in pharmaceutical industry, fast innovations in animal models, and rising demand for personalized medicine are primary factors fueling revenue growth of the market.
Growing demand for novel therapeutics has resulted in increased R&D activities to search for advanced vaccines or drugs. In addition, animal testing is mandatory for determining toxicology profiles, especially for new drugs. These factors are predicted to augment the demand for in-vivo toxicology testing products, propelling the revenue growth of the market going ahead. Furthermore, rapid technical advances in various animal models are also contributing to the revenue growth of the in-vivo toxicology testing market.
However, growing ethical concerns regarding the use of animal models could hinder the market revenue expansion to a certain extent in the coming years. Moreover, questions over the validity of animal models in demonstrating long term toxicity may hamper the market revenue growth.
Major players operating in the market are The Jackson Laboratory (U.S.), Charles River Laboratories (U.S.), Envigo (U.S.), JANVIER LABS (France), Taconic Biosciences, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Waters Corporation (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), and PerkinElmer (U.S.). Get a Free Sample now@ https://www.reportsanddata.com/sample-enquiry-form/4022
Further key findings in the report
In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the U.S. Department of Health and Human Services, declared funding for projects for conducting detailed characterization, direct comparisons, along with further development of Humanized Immune System (HIS) mouse models.
The animal models segment is predicted to register the highest revenue share in the market going ahead. This segment includes various animals including rats, mice, primates and cattle, etc. Increasing clinical trials combined with the growing advancements in animal models are fueling the segment revenue growth.
North American market is expected to account for largest revenue share in the global market during the forecast period. This high revenue share is attributed to presence of prominent players operating in the regional market, rising biomedical research in the U.S., and growing preclinical activities by pharmaceutical companies and CROs in North America.
For the purpose of this report, Reports and Data has segmented the global in vivo toxicology market on the basis of product, test type, toxicity endpoints, testing facility, end user, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2028)
Instruments
Consumables
Reagents & Kits
Animal Models
Mice Models
Rat Models
Other Animal Models (Guinea Pigs, Hamsters, Rabbits, and Human Primates)
Test Type Outlook (Revenue, USD Billion, 2018 - 2028)
Acute
Sub-acute
Sub-chronic
Chronic test type
Testing Facility Outlook (Revenue, USD Billion, 2018 - 2028)
Outsourced testing facility
In-house testing facility
Toxicity End Point Outlook (Revenue, USD Billion, 2018 – 2028)
Immunotoxicity
Systemic toxicity
Carcinogenicity
Genotoxicity
Developmental & reproductive toxicity (DART)
Other toxicity endpoints
End User Outlook (Revenue, USD Billion, 2018 – 2028)
Academic and Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Other End Users
Regional Outlook (Revenue, USD Billion, 2018 - 2028)
U.S.
Canada
Mexico
Germany
UK
France
Italy
Spain
BENELUX
Rest of Europe
China
India
Japan
South Korea
Rest of APAC
Saudi Arabia
UAE
South Africa
Rest of MEA
Access Full Report Details @ https://www.reportsanddata.com/press-release/global-in-vivo-toxicology-market
Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
0 notes
sandlerresearch · 4 years ago
Text
Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026 published on
https://www.sandlerresearch.org/patient-derived-xenograft-pdx-model-market-by-type-mouse-rat-tumor-type-gastrointestinal-gynecological-hematological-application-preclinical-drug-development-biomarker-analysis-end-user.html
Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026
“Rising pharmaceutical R&D spending is driving the overall growth of the PDX models market”
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD  299 million by 2026 from USD  140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.
“The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period”
The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment’s high growth rate can be attributed to the rising number of clinical trials every year.
“Contract research organizations segment accounted for the highest CAGR”
Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
“Rat models segment accounted for the highest CAGR”
Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.
“Respiratory tumor models segment accounted for the highest CAGR”
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment’s growth is the increasing incidence of lung cancers globally.
“Asia Pacific: The fastest-growing country in the PDX models market”
The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 70%, and Demand Side – 30%
By Designation (Supply Side): Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
JSR Corporation (Japan)
 WuXi AppTec (China)
Champions Oncology, Inc. (US)
 THE JACKSON LABORATORY (US)
Charles River Laboratories (US)
Oncodesign (France)
 Envigo (US)
Pharmatest Services (Finland)
Hera BioLabs (US)
EPO Berlin-Buch GmbH (Germany)
Xentech (France)
Urosphere (France)
Abnova Corporation (Taiwan)
Genesis Biotechnology Group (US)
Explora BioLabs (US)
Biocytogen (US)
Living Tumor Laboratory (Canada)
Bioduro (US)
Aragen Life Sciences w.e.f, (US)
Shanghai Lide Biotech Co., Ltd. (China)
Research Coverage:
This report provides a detailed picture of the PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, tumor type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall PDX models market and its sub segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
0 notes
newmarketplace · 4 years ago
Text
What Would Be The Scope Of The Humanized Mice Model Market In The Next 10 Years?
Persistence Market Research (PMR) has published a new research report on humanized mice model. The report has been titled, “Humanized Mice Model Market: Global Industry Key Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2026.” In order to extemporize pre-clinical studies, humanized mice models surface as a better solution. With further development in genomic analysis, there is also a chance of refinement in the mouse models.
Humanized mice models have been in use mice for better understanding of the disease, in order to design effective therapies, create accurate models of drug metabolism and improve the understanding of mammalian and human genome function. Market players are incessantly competing for a significant value share and expansion of their global outreach by investing in technologies.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22714
Company Profiles
THE JACKSON LABORATORY
Taconic Biosciences, Inc.
Genoway S.A.
Yecuris Corporation
Charles River Laboratories, Inc.
Crown Bioscience Inc.
Ingenious Targeting Laboratory Inc.
orizon Discovery Group plc
HuMurine Technologies
Trans Genic Inc., Ltd.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22714  
With growing need to develop better varieties of humanized mice model and improve the quality and outcome of research studies, the demand for humanized mice models is increasing. However, various technical restrictions may pose as a challenge for the development of the market. Some of the leading companies operating in the market are The Jackson Laboratory, Crown Bioscience Inc. (JSR Life Science), Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Ingenious Targeting Laboratory Inc., Trans Genic Inc., Ltd., GenOway, Creative Animodel, and Horizon Discovery Group plc.
According to the report, the global humanized mice model market is projected to exhibit a CAGR of 6.0% from 2017 to 2026. In 2017, the market was worth US$ 67.5 Mn and it has been estimated that it will touch a valuation of US$ 113.5 Mn by the end of 2026.
Technological Development to Trigger Demand for Humanized Mice Models
Novel technologies are being developed with each passing day, which permit robust genetic modification of mice, which accelerates the development of new immune deficient mice models for capitalizing on the discovery of novel approaches to enhance the engraftment of human cells or tissues.
Moreover, speedy technological advancements have been witnessed in the last 20 years, which comprise the genetic engineering of mouse genome such as the development of knock-out mouse, knock-in mouse as well as the transgenic mouse.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/22714
The aptitude to engraft mouse liver with human hepatocytes and mouse bone marrow with human hematopoietic stem cells is also foreseen to provide new opportunities, proliferating the market growth. These models also overcome the limitations of xenograft models as they elucidate disease etiology, tumor progression and metastasis.
Moreover, humanized mice strains provide better research models than working with mutant mouse protein. They are considered as more realistic models for tumor studies than the dish-grown cancer cells, and are also used for safety evaluation when neither normal mice nor rats can be used in particular biologics.
Availability of Substitutes to Hinder Market Growth
In addition to mice, other genetically modified species that can be used as models are being carefully measured for research purpose. Lately, knockout of CFTR gene has been stated in the pig as it is similar in size to humans and may be a superior model for the research on cardiovascular and metabolic diseases. Experimental advancements employing computer simulation, in silico, in vitro, and other non-animal approaches are also being taken up for the replacement of animal studies.
About us:
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact Us:                                                                                                    
Persistence Market Research Address – 305 Broadway, 7th Floor New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected]
0 notes
healthcaremarketanalysis · 5 months ago
Text
Global Humanized Mouse and Rat Model Market worth $349 million by 2028
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.
Tumblr media
Download an Illustrative overview:
Browse in-depth TOC on "Humanized Mouse and Rat Model Market"
140 - Tables
27 - Figures
188 – Pages
The North American market is projected to contribute the largest share for the humanized mouse and rat model industry
The global humanized mouse and rat model market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for humanized mouse and rat model market in 2022, while Europe is the second-largest market. US has emerged as the key revenue contributor to this region. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the US in 2023.
Humanized Mouse and Rat Model Market Dynamics:
Drivers:
Increasing research activities using humanized models
Rising demand for personalized medicine
Continuous support and initiatives from government and private sectors for cancer research
Growing R&D activities in pharmaceutical and biotechnology sectors
Restraints:
High cost of custom humanized models
Laws and regulations for ethical use of animal models in research
Opportunities:
Rising demand for humanized PDX models
Emergence of CRISPR as a powerful tool in biomedical research
Rising demand for humanized rat models
Challenges:
Alternatives for animal testing
Limitations of humanized mouse models
Key Market Players:
The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955
Recent Developments:
In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.
In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.
Humanized Mouse and Rat Model Market Advantages:
Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.
Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.
Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.
Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.
Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.
Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.
Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.
Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.
Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.
Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.
Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.
Related Links:
https://www.prnewswire.com/news-releases/humanized-mouse-and-rat-model-market-worth-349-million--marketsandmarkets-301882836.html
0 notes
tritonmarketresearch · 4 years ago
Text
The Global Stem Cell Market to Progress at CAGR of 7.54% by 2028
Triton Market Research presents the Global Stem Cell Market report segmented by Technology (Expansion and Sub-Culture, Acquisition [Stem Cell Bone Marrow Market, Stem Cell Umbilical Cord, Stem Cell Apheresis], Cryopreservation, Production [Therapeutic Cloning, IVF, Stem Cell Culture]), Therapeutic Application (Orthopedic Treatments, Diabetes, Neurological Disorders, Cardiovascular Disorders, Oncology Disorders, Injuries and Wounds, Other Therapeutic Applications), Application (Drug Discovery and Development, Regenerative Medicine), Treatment Type (Autologic Stem Cell Therapy, Syngeneic Stem Cell Therapy, Allogeneic Stem Cell Therapy), Product (Human Embryonic Stem Cell, Mouse/Rat Neural, Adult Stem Cell [Umbilical Cord Stem Cell, Hematopoietic Stem Cell, Mesenchymal Stem Cell, Neural Stem Cell, Dental Stem Cell], Pluripotent), and Geography (Asia-Pacific, Middle East and Africa, North America, Latin America, Europe). The report also discusses the Market Summary; Industry Outlook; Porter’s Five Forces Model; Impact of COVID-19; Key Impact Analysis; Industry Components; Legal, Policy, & Regulatory Framework; Market Attractiveness Index; Vendor Scorecard; Key Insights; Drivers; Restraints; Opportunities; Company Profiles; Research Methodology & Scope; Global Market Size; Forecasts & Analysis (2021-2028).
Tumblr media
Triton’s report estimates the global stem cell market to display growth at 7.54% of CAGR during the assessed years of 2021-2028.
Request a Free Sample: https://www.tritonmarketresearch.com/reports/stem-cell-market#request-free-sample
Stem cells display immense potential for dermal tissue regeneration, along with promoting wound repair in a paracrine manner. Moreover, numerous types of cells, including hematopoietic stem cells and embryonic stem cells, are under examination to treat various chronic conditions, which might contribute to the studied market’s growth.
Factors such as advancement in technology, coupled with the risk of adverse immune reactions and complications, are anticipated to open multiple growth avenues for the stem cell market’s development across all regions. For instance, conventional tissue or organ transplant procedures involve specific risks of immune reactions due to incompatible HLA. However, stem cell transplant does not include the threat of donor tissue attacking the host cells. Hence, stem cell transplants have a certain advantage over traditional transplant procedures, which further contributes to the growth of the stem cell market.
However, ethical concerns pertaining to stem cells, the high cost of stem cell procedures, and strict stem cell therapy regulations significantly weigh down the growth of the stem cell market.
Globally, North America holds the largest market for stem cell, and is expected to continue dominating the studied market till 2028. The region’s dominance is due to multiple reasons, such as surged investments in research and development activities relating to stem cells and other pharmaceuticals. Moreover, the high prevalence of chronic conditions in the United States and Canada, is also boosting the market for stem cell. Among the countries, the United States has a well-developed healthcare infrastructure, with several products in line for stem cell therapies. Thus, these factors indicate a robust growth of the stem cell market across North America during the forecast period.
The renowned companies engaged in this market consist of StemCell Technologies, Becton Dickinson and Company (BD), International Stem Cell Corp, AllCells LLC, Takara Holdings, Thermo Fisher Scientific Inc, Cytori Therapeutics, Miltenyi Biotec, Qiagen NV, Smith & Nephew Plc, Merck KGAA (Sigma Aldrich), Stryker Corporation, Corning Inc, GE Healthcare, and Pluristem Therapeutics Inc.  
The stem cell market is highly based on research activities undertaken by academic and biopharmaceutical companies to detect new therapies for treating several diseases. The investment in the market is high, and includes collaborative efforts to be taken by new players. Here, the market relies mainly on the safety and efficiency of stem cell products, which is likely to make the threat of new players likely remain moderate. However, several existing companies are surging their R&D activities for developing novel stem cell therapies, with many concentrating on extending their expertise in the area of regenerative medicines. This indicates the intensity of the competition among the current players to be relatively high during the considered phase.
 Contact Us: [email protected]
Phone: +44 7441 911839
0 notes